Clinical Trial

Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 12, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, open-label, controlled clinical trial that prospectively enrolls 100 participants (40 in the Z11020076 group, 40 in the Z20063878 group, and 20 in the blank control group) to collect clinical data, imaging data, and biospecimens over an 84-day follow-up period. The primary objective is to compare the efficacy and safety of Angong Niuhuang Pills from Beijing Tongrentang (Approval No. Z11020076) and Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. (Approval No. Z20063878) in improving clinical functional outcomes and prognosis in acute ischemic stroke (AIS) patients. The secondary objective is to evaluate the interventional effects of Angong Niuhuang Pills with different bovine bezoar formulation sources on gut microbiota diversity and composition, peripheral blood immune function, and inflammatory status in AIS patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2026-01-09.
Status change: Not Yet Recruiting → Recruiting 2026-01-09
Trial Details
NCT Number NCT06883110
Lead Sponsor Tongji Hospital
Conditions Acute Ischemic Stroke
Enrollment 100 participants
Start Date 2025-09-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-12